This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in North Dakota
Licensed North Dakota practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. North Dakota buyers need their own professional license and NPI; the wholesale drug distributor license is the supplier’s obligation, not the purchaser’s.
North Dakota is worth understanding on its own terms. Nurse practitioners have practiced without a collaborative agreement since 2011, and HB 1175 made it the first state to adopt the core of Optimal Team Practice for physician assistants in 2019. Ownership is the counterweight: the state sits at the strict end of the corporate practice spectrum, so the structure question deserves more attention here than the delegation question.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Dakota del Norte? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | No |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Dakota del Norte
ExaVeyra ships to licensed practices in all 50 states, North Dakota included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active North Dakota professional license in good standing, verifiable through the North Dakota Board of Medicine or the North Dakota Board of Nursing.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A North Dakota sales and use tax permit and resale documentation through the Office of State Tax Commissioner if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
North Dakota licenses wholesale drug distributors through the Board of Pharmacy under Century Code chapter 43-15.3, a chapter titled Wholesale Drug Pedigree, a name left over from the mid-2000s pedigree era. Section 43-15.3-03 carries the licensing requirement: a wholesale distributor located in North Dakota or in any other state that engages in wholesale distribution of prescription drugs into the state is licensed by the Board before distributing. The chapter separately addresses distribution of prescription drugs, medical gases, and medical equipment in section 43-15.3-04. The license sits with the distributor, not with the purchasing practice.
N.D. Cent. Code ch. 43-15.3; N.D. Cent. Code § 43-15.3-03 · North Dakota Board of Pharmacy
Dakota del Norte regenerative-medicine law
Dakota del Norte has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
No North Dakota statute addresses unapproved regenerative therapy, so federal law is the only layer that applies. The nearest thing in the Century Code is chapter 23-48, Experimental Drugs, the right to try act enacted as SB 2259 in 2015. It lets a manufacturer make an investigational drug, biological product, or device that has cleared Phase 1 of an FDA-approved trial available to a patient with a terminal illness attested by the treating physician, and it shields a provider’s license for recommendations consistent with the standard of care. That is a patient-access statute running through manufacturers and treating physicians; it is not an authorization for a clinic to offer regenerative therapy, and it does not define or regulate stem cells. Clinical practice in this area is governed by the Medical Practice Act, the Nurse Practices Act, and the boards that administer them.
How this applies to exosomes
North Dakota has not enacted a stem cell authorization law like Florida, Texas, or Georgia, a disclosure law like California, or a documentation statute like Tennessee. Chapter 23-48 is sometimes raised in this context, and it does not fit: it reaches investigational products for terminally ill patients through their manufacturers and treating physicians, and it conditions access on FDA trial status rather than authorizing any standing clinical service. There is accordingly no North Dakota definition to read exosomes into or out of, and nothing in state law reaches acellular extracellular vesicles. Exosome products are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Dakota del Norte practice
The practical consequence is that North Dakota offers three workable structures rather than one: a physician-led practice that delegates conventionally, an APRN-led practice operating in full practice authority, and an experienced PA-led practice under HB 1175 with board approval. What the state gives in delegation it takes back in ownership, so the planning effort belongs on entity structure. License verification runs through the Board of Medicine, the Board of Nursing, and the Board of Pharmacy, each on its own site.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the North Dakota Board of Medicine may perform medical acts within their scope and are the source of delegation to staff who do not hold independent authority. The same board licenses physician assistants. |
| NP / APRN | North Dakota is a full practice authority state. The 2011 legislature removed the collaborative agreement requirement, so an advanced practice registered nurse evaluates, diagnoses, and prescribes within APRN scope without a physician agreement, with prescriptive practices addressed at section 43-12.1-08.1 of the Nurse Practices Act. |
| PA | HB 1175 (2019) made North Dakota the first state to adopt the key elements of Optimal Team Practice. A physician assistant no longer needs a written agreement with a specific physician in most settings, including licensed facilities and practices with credentialing processes, and collaboration is determined at the practice level. A PA may own a practice with Board of Medicine approval; an owner with fewer than 4,000 practice hours maintains a collaborating physician. |
| RN | Registered nurses perform delegated nursing interventions within their scope under the Nurse Practices Act, which addresses supervision and delegation at section 43-12.1-16.1, and only after a patient evaluation and an order from a provider with authority to issue one. An RN does not diagnose, prescribe, or independently select a treatment. |
Good faith examination
North Dakota expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Given full practice authority, that provider can be a physician, an APRN, or a physician assistant acting within scope. Confirm current expectations with the Board of Medicine and the Board of Nursing, since this area is governed by board interpretation rather than a single statute.
Ownership and clinic licensing
North Dakota sits at the strict end of the corporate practice spectrum. Professional entities are organized by licensees of the profession they practice, and the Century Code treats employment of physicians by anyone else as an exception it has to spell out: section 43-17-42 permits hospitals, nonprofit entities, and charitable trusts to employ physicians under a written contract, which is the kind of carve-out a state only writes against a background prohibition. A management services arrangement for a med spa or aesthetic practice is therefore a structure to build with North Dakota counsel rather than to import from a permissive state.
Cold chain into Dakota del Norte
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Dakota del Norte order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Fargo | Cass | Largest North Dakota market, serving practices on both sides of the Minnesota border. |
| Bismarck | Burleigh | Capital market with a broad clinical base. |
| Grand Forks | Grand Forks | University market in the Red River Valley. |
| Minot | Ward | Regional hub for the northwest of the state. |
| West Fargo | Cass | Fast-growing suburb served on the Fargo lane. |
- North Dakota orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Vials arrive frozen with the manufacturer’s handling instructions and the Certificate of Analysis for the lot; follow the insert for storage on arrival.
Practice types we supply in Dakota del Norte
Dakota del Norte licensing and verification
North Dakota Board of Medicine
Licenses physicians and physician assistants, and approves PA practice ownership.
North Dakota Board of Nursing
Licenses RNs and APRNs; North Dakota APRNs hold full practice authority.
North Dakota Board of Pharmacy
Licenses the wholesale drug distributors that ship into the state.
North Dakota Office of State Tax Commissioner
Sales and use tax permits and resale documentation.
Dakota del Norte sourcing questions
- Does North Dakota have a stem cell law?
- No. North Dakota has no stem cell authorization, disclosure, or documentation statute. The nearest law is chapter 23-48 of the Century Code, the Experimental Drugs chapter enacted as SB 2259 in 2015, a right to try act that lets manufacturers make Phase-1-cleared investigational products available to terminally ill patients. It is a patient-access statute, not a clinic authorization, so exosome products in North Dakota are governed by federal law.
- Are exosome products FDA approved?
- No exosome product is FDA approved for administration to humans, in North Dakota or anywhere else, and the FDA has issued a public safety notification about clinics marketing unapproved exosome products. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot documentation on every vial.
- Can a nurse practitioner practice independently in North Dakota?
- Yes. North Dakota removed the collaborative agreement requirement in 2011 and is a full practice authority state, so an APRN evaluates, diagnoses, and prescribes within APRN scope without a physician agreement. An APRN-led aesthetic practice is a workable structure here, with entity and ownership questions still worth running past North Dakota counsel.
- What changed for physician assistants in North Dakota?
- HB 1175 (2019) made North Dakota the first state to adopt the key elements of Optimal Team Practice. A PA no longer needs a written agreement with a specific physician in most settings, collaboration is determined at the practice level, and a PA may own a practice with Board of Medicine approval, keeping a collaborating physician until reaching 4,000 practice hours.
- Does my North Dakota clinic need a wholesale license to buy exosomes?
- No. The wholesale drug distributor license under N.D. Cent. Code 43-15.3-03 is held by the distributor shipping into North Dakota, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- How long does cold-chain shipping take to North Dakota?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- N.D. Century Code ch. 43-15.3, Wholesale Drug Pedigree (wholesale distributor licensing) (accessed 16 October 2026)
- N.D. Century Code ch. 23-48, Experimental Drugs (right to try) (accessed 16 October 2026)
- N.D. Century Code ch. 43-12.1, Nurse Practices Act (accessed 16 October 2026)
- N.D. Century Code ch. 43-17, Physicians and Surgeons (accessed 16 October 2026)
- North Dakota HB 1175 (2019), bill overview (accessed 16 October 2026)
- North Dakota Board of Pharmacy (accessed 16 October 2026)
- North Dakota Board of Nursing (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The field’s current characterization standard for extracellular vesicles, the benchmark behind the COA and lot documentation this page says accompanies every North Dakota shipment.
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 2019. doi:10.1080/20013078.2019.1609206 PMID:31069028Consensus statementsupports: Sets out what an MSC-derived small EV preparation must demonstrate, supporting this page’s description of perinatal MSC-derived exosome source material and its documentation standard.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing, safety, and regulatory expectations for EV-based products, the context for this page’s statement that no exosome product holds FDA approval.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.